comparemela.com

Page 2 - Cambridge Allergy Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Worldwide Food Allergy Diagnostics & Therapeutics Industry to 2027 - Increasing Incidences of Allergic Diseases is Driving Growth

Cambridge Allergy Ltd: Camallergy Awarded £1 1 M Funding Under Innovate UK Biomedical Catalyst Award for Novel Peanut Allergy Treatment

Cambridge Allergy Ltd: Camallergy Awarded £1.1 M Funding Under Innovate UK Biomedical Catalyst Award for Novel Peanut Allergy Treatment -Company to provide corporate update at upcoming Global Life Sciences investor conference Cambridge Allergy Ltd ( Camallergy or the Company ), a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded £1.1M funding under the Innovate UK Biomedical Catalyst Award program administered by Innovate UK, the United Kingdom s research and innovation agency. The £1.1M in non-dilutive funding will be used to accelerate the Company s peanut allergy immunotherapy, CA002, for planned Phase 3 clinical trials. The project commences in the first quarter of 2021, and as part of the project s success, the Company intends to file its investigation new drug application with the FDA and submit a clinical trials application to the MHRA and EMA.

Camallergy s UK Based Manufacturing Facility Receives cGMP Licences for Peanut Allergy Treatment

Share: -Facility to supply drug product for planned Phase 3 clinical trials and early access programme Cambridge Allergy Ltd ( Camallergy or the Company ), a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced that its manufacturing facility outside of Portsmouth, United Kingdom was approved by the MHRA, the Medicines and Healthcare products Regulatory Agency, to manufacture its proprietary peanut allergy treatment under current Good Manufacturing Practices (cGMP) standards. This clearance is a pivotal regulatory milestone that further supports Camallergy s leadership and capabilities in the field of peanut allergy immunotherapy with the only cGMP-certified manufacturing facility in Europe producing peanut oral immunotherapy, said Sherden Timmins, Chief Technology Officer.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.